|
Published by: Datamonitor
Published: Apr. 26, 2005 - 124 Pages
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the disease market
- Market definition for this report
- CHAPTER 2 MARKET DYNAMICS
- Current market: US accounts for 63% of global respiratory sales
- Asthma/COPD: GSK's "Super Advair" sets the new gold standard
- Allergic rhinitis: Merck develops a "Super Singulair" combination?
- CHAPTER 3 PATIENT POTENTIAL
- Asthma patient potential
- Definition and etiology of asthma
- Treatment options
- Prevalence of asthma
- Segmentation of asthma
- COPD patient potential
- Definition and etiology of COPD
- Treatment options
- Prevalence of COPD
- Segmentation of COPD
- Allergic rhinitis patient potential
- Definition and etiology of allergic rhinitis
- Treatment options
- Prevalence of allergic rhinitis
- Segmentation of allergic rhinitis
- CHAPTER 4 ASTHMA R&D PIPELINE
- Combination ICS/LABAs: GSK race to develop once-daily formulation
- GSK first to market with once-daily LABA/ICS, but US launch ominously close to Advair patent expiry
- Novartis/Schering-Plough alliance most significant threat to GSK
- Sanofi-Aventis/Altana lack once-daily LABA; AstraZeneca US launch of Symbicort delayed
- AstraZeneca Symbicort US launch uncertain
- Sanofi-Aventis/Altana's ciclesonide/formoterol combination dependant on gaining US approval at the highest 320ìg dose for Alvesco monotherapy
- Boehringer Ingelheim unlikely to develop ICS/LABA combination
- Few in-licensing opportunities in long-acting beta-2 agonist class
- Inhaled Corticosteroids: Alvesco and Asmanex will struggle with positioning
- Alvesco's EU launch handicapped by 160µg maximum dose
- Asmanex finally gains approval in US
- Oral non-steroidal anti-inflammatories: Singulair to face competition before patent expiry in 2012
- Merck targeting a Singulair/PG-D2 combination?
- CCR3 antagonists most likely to threaten Singulair
- Future of oral VLA-4 antagonists decided in 2005
- PDE-IV inhibitors - limited prospects in asthma
- The mast cell: time for revaluation in asthma
- Severe asthmatics remain a challenging population
- Monoclonal antibodies: can blockade of a single target work?
- Xolair to achieve peak sales of $890m
- Anti-IL-13 mAb offers potential for disease modification
- Roche and Wyeth target severe asthma with Zenapax and Enbrel
- Inhaled immunostimulatory DNA - correcting the Th1/Th2 imbalance
- Can Novartis's Elidel reduce the risk of developing asthma?
- Role for novel COPD therapies in severe neutrophilic asthma?
- Short-acting B2-agonists: generic CFC converts to a HFA branded market
- Sepracor's Xopenex to capture 50% of albuterol HFA market
- Gene therapy: Topigen's ASM-8 enters Phase I
- Airway remodeling: dominant molecular mechanism yet to emerge
- CHAPTER 5 COPD R&D PIPELINE
- Long-acting antimuscarinics: novel inhaled "Spiriva" combinations the next battleground
- GSK develop next-generation Spiriva
- Pfizer/BI, GSK and Novartis target novel long-acting LAMA/LABA combinations
- Novel triple combinations on the horizon
- Limited licensing opportunities in antimuscarinic class
- Novel oral anti-inflammatories: modest uptake will generate significant revenues
- PDE-IV inhibitors: Daxas to reach market in 2006
- Daxas - awaiting 12-month efficacy data
- Ono or Merck expected to launch second-to-market oral PDE-IV inhibitor
- CXCR2 antagonists - a focus for GSK, AZ and Schering-Plough?
- Restoring the proteinase-antiproteinase balance
- Search for disease-modifying therapy continues
- CHAPTER 6 ALLERGIC RHINITIS R&D PIPELINE
- Novel oral anti-inflammatories: Singulair/PG-D2 combination for allergic rhinitis?
- Singulair's status as an asthma drug protects its low co-pay classification
- PG-D2 antagonists may address nasal congestion
- Novel intranasal non-steroidal therapies
- Pfizer has limited option to license Rigel's R-112 for allergic rhinitis
- Evolutec's "Tick saliva" - the new antihistamine?
- Biolipox's NCX-1510 - the gold standard intranasal antihistamine?
- Incremental innovation in established classes
- GSK's Allermist US launch most significant near-term event
- Novel oral antihistamines struggle to offer differentiation to current market leaders
- Xyzal succeeds Zyrtec in US?
- Gap in market for improved allergen vaccination technologies
- Oral allergen tablets will considerably simplify treatments
- Novel "Immunodrug" approaches may have vastly improved delivery schedules
- CHAPTER 7 COMPANY PORTFOLIO ANALYSIS
- GSK leads in inhaled therapy, but lacks an oral anti-inflammatory
- AstraZeneca has a broad early development pipeline in asthma and COPD
- Novartis requires partner to be successful in inhaled therapies
- Merck's future lies in developing a Singulair/PG-D2 combination product
- Pfizer/BI building franchise in COPD around Spiriva combinations
- Sanofi-Aventis's pipeline lacks a blockbuster product
- CHAPTER 8 APPENDIX
- Asthma/COPD sales mix - what are asthma and COPD products used for?
- Launch forecasting methodology
- Compounds in clinical development for asthma, COPD and allergic rhinitis
- References
- About Datamonitor
- About Datamonitor Healthcare
- About the Respiratory & Infectious Diseases analysis team
- Disclaimer
- List of Figures
- Figure 1: Asthma/COPD and allergic rhinitis sales ($m) and market share (%) by class, in US and 5EU, 2004
- Figure 2: Global sales in asthma/COPD 2005-15, by launched and development products
- Figure 3: Global sales in asthma/COPD ($m), 2005 & 2015, by class
- Figure 4: Global sales in allergic rhinitis ($m), 2005 & 2015, by class
- Figure 5: Eosinophils and mast cells are central to the pathophysiology of atopic asthma
- Figure 6: The inflammation associated with COPD involves neutrophils and alveolar macrophages
- Figure 7: Global forecast sales of combination ICS/LABA products ($m), 2005-15
- Figure 8: GSK will set the new gold standard in the combination therapy class from 2010
- Figure 9: Launch forecasts for inhaled corticosteroid/long-acting beta-2 agonist fixed combinations
- Figure 10: Advantages and disadvantages of Altana's Alvesco
- Figure 11: Novel oral anti-inflammatories - balancing safety with efficacy
- Figure 12: Global forecast sales in asthma for Singulair and Singulair/PG-D2 combination product ($m), 2005-15
- Figure 13: CCR3 antagonists and Singulair/PG-D2 combination hold greatest promise in oral anti-inflammatory class
- Figure 14: Launch forecasts for novel oral anti-inflammatories
- Figure 15: Wyeth's efipladib has a broad anti-inflammatory profile
- Figure 16: Forecast sales of Xolair and second-to-market monoclonal antibody ($m), 2005-15
- Figure 17: 74,000 patients treated with Xolair by 2010, 74% in US market
- Figure 18: Global forecast sales of Xopenex-HFA and Xopenex inhalation solution ($m), 2000-10
- Figure 19: Launch forecasts for compounds in clinical development for asthma
- Figure 20: Global forecast sales of antimuscarinic class ($m), 2005-15
- Figure 21: Novel triple combinations on the horizon
- Figure 22: Results from roflumilast RECORD study in patients with moderate-to-severe COPD
- Figure 23: Sales forecast for Daxas in EU and US ($m), 2005-15
- Figure 24: Targets for future COPD therapy
- Figure 25: Launch forecasts for products in clinical development for COPD
- Figure 26: Global forecast sales for Singulair and Singulair/PG-D2 combination product in allergic rhinitis ($m), 2005-15
- Figure 27: US sales for intranasal corticosteroid ($m), 2005-15
- Figure 28: EU sales of Zyrtec and Xyzal in allergic rhinitis ($m), 2000-04
AbstractIntroduction
The asthma, COPD and allergic rhinitis global market was $25.5 billion in 2004, with five brands selling over $1.0 billion. While a number of moderately successful launches are expected within the next five years, companies are seeking novel combination therapies to create the next generation of blockbuster drugs.
Scope
- Evaluation of over 75 drugs in clinical development for asthma, COPD, and allergic rhinitis, including launch forecasts
- Opinion leader insight into early stage therapies and treatment strategies
- Forecasts of key late-stage therapies: Alvesco (ciclesonide), Daxas (roflumilast), Xolair (omalizumab), Xopenex (levalbuterol)
- Forecasted sales of the respiratory market in the next 10 years, exploring the potential impact of early phase therapies
Highlights
Inhaled corticosteroid/long-acting b2-agonist fixed combinations will remain the leading asthma/COPD class in 2015, almost exclusively represented by sales of GSK's "Super Advair", with its once-daily profile setting the new gold standard.
Merck may invigorate the oral asthma market through the development of a Singulair/ prostaglandin-D2 combination product, while monoclonal antibodies will be the fastest growing asthma class, with therapies that are effective in non-atopic asthma having a $1.0 billion sales opportunity.
Novel, long-acting, dual-action bronchodilator combinations will expand the COPD market from 2012, with novel triple combinations on the horizon. Altana/Pfizer's Daxas will achieve peak sales of $750 million by 2010, although 12-month data and combination trials with Spiriva will be key to success.
Reasons to Purchase
- Understand unmet needs in the respiratory market, and how late-stage compounds address these needs
- Identify potential licensing opportunities for respiratory market entry or portfolio expansion
- Benchmark key late-stage asthma and COPD compounds against market leaders
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
